Astellas Pharma Inc. (ALPMY)
Quick facts
| Ticker | ALPMY (OTC) |
|---|
Marketed products
- Xtandi · Oncology · revenue 4500
Xtandi works by blocking the androgen receptor, a protein that helps prostate cancer cells grow. - Padcev · Oncology · revenue 2300
Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction. - Prograf · Immunology · revenue 1600
Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell. - Xospata · Oncology · revenue 600
Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor. - Evrenzo · Hematology · revenue 600
- Vyloy · Oncology · revenue 100
Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction. - Adenocard · Neuroscience
- Amevive · Immunology
- Cyclocort · Oncology
- Abelcet · Immunology
- ATG-F · Other
- Izervay · Immunology
Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response. - Padcev Ejfv · Oncology
Enfortumab vedotin-ejfv binds to Nectin-4, internalizes, releases MMAE, disrupting microtubules and causing cell death. - Veozah · Neuroscience
Veozah works by binding to the Neuromedin-K receptor, which helps to alleviate vasomotor symptoms. - Bisphonal · Bone
- Cresemba · Infectious Disease
Isavuconazonium sulfate is a prodrug that converts to isavuconazole, an azole antifungal. - Enfortumab · Oncology
- Vesicare · Urology
Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency. - Xtandi · Oncology
Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction. - VYLOY · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: